Efficacy of magnesium in patients with TMD: clinical trial

Evaluation of the efficacy of magnesium in patients with Myofascial Temporomandibular Disorder: a triple-blind randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-65gns68

Enrollment

Unknown

Registered

2025-06-10

Start date

2024-01-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Pain

Interventions

D26

This is a three-arm, triple-blind, randomized controlled clinical study. A total of 30 People who meet the eligibility criteria will be probabilistically allocated to one or another group intervention

Eligibility

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Participants aged between 18 and 31 years old; patients with myofascial Temporomandibular Disorder (TMD); patients without associated comorbidities; patients without a history of allergies; patients without a history of kidney or liver injury; patients who sign the free and informed consent form for the research; female and male patients

Exclusion criteria

Exclusion criteria: Patients with joint problems; patients using other medications to control pain; patients who use dietary supplements to increase sports performance; patients who refuse to participate in the research; patients presenting chronic pain; patients with severe pain who require other adjuvant therapies; patients with minimal pain, according to the visual analogue scale (VAS) < 3; pregnant patients; hyperthyroidism; patients using antidepressants; cardiac patients; patients suffering from Glaucoma; patients who use alcoholic beverages during the treatment period

Design outcomes

Primary

Measure	Time frame
It is expected not to find a statistically significant difference in the effectiveness of the use of Magnesium Citrate in the treatment of patients with (SDAT) versus Cyclobenzaprine Hydrochloride, assessed through algometry examination, measurement with a digital caliper and DC/TMD assessment. Data collected 7, 14 and 21 days after the intervention.;It is expected to find a statistically significant difference in the effectiveness of the use of Magnesium Citrate in patients with (SDAT) versus the use of Cyclobenzaprine Hydrochloride, evaluated by means of an algometry examination, measurement with a digital caliper and DC/TMD assessment. Data collected 7, 14 and 21 days after the intervention.	—

Measure

Time frame

It is expected not to find a statistically significant difference in the effectiveness of the use of Magnesium Citrate in the treatment of patients with (SDAT) versus Cyclobenzaprine Hydrochloride, assessed through algometry examination, measurement with a digital caliper and DC/TMD assessment. Data collected 7, 14 and 21 days after the intervention.;It is expected to find a statistically significant difference in the effectiveness of the use of Magnesium Citrate in patients with (SDAT) versus the use of Cyclobenzaprine Hydrochloride, evaluated by means of an algometry examination, measurement with a digital caliper and DC/TMD assessment. Data collected 7, 14 and 21 days after the intervention.

—

Secondary

Measure	Time frame
No secondary outcomes are expected.	—

Countries

Brazil

Contacts

Public ContactMiqueias Junior

Universidade de Pernambuco

miqueias_lima_junior@hotmail.com+55(81)989862735

Outcome results

None listed

Source: REBEC (via WHO ICTRP)